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Figure 1. Activation mechanism of DYRKs and functions in cell-cycle regulation 
and neurodegeneration.
(A) DYRKs self-activate by one-time tyrosine autophosphorylation. The cartoon illustrates the 
hypothesis that the phosphotyrosine stabilizes the active conformation of the catalytic domain 
(cat). (B) DYRKs promote cell-cycle exit. Phosphorylation by DYRKs promotes proteasomal deg-
radation of cyclin D1 and c-Myc, which drive S-phase entry. Antiproliferative CDK inhibitors are 
transcriptionally upregulated (p21Cip1) or stabilized (p27Kip1). (C) Proposed role of DYRK1A in Alz-
heimer’s disease. DYRK-mediated hyperphosphorylation of the tau protein induces dissociation of 
tau from the microtubules, destabilization of microtubules and aggregation of tau in paired helical 
fi laments, which cause neurotoxicity. DYRK protein 
kinases 
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What are DYRKs? The designation 
DYRK (for ‘dual-specifi city tyrosine 
(Y) phosphorylation-regulated kinase’) 
highlights the peculiar biochemical 
characteristics of this protein kinase 
family. The hallmark of dual-specifi city 
protein kinases is their ability to 
phosphorylate aromatic (tyrosine) as 
well as aliphatic (serine and threonine) 
amino acid residues.
But what is the point of dual 
specifi city? Like other functionally 
related kinases, kinases of the DYRK 
family need to be activated before they 
can phosphorylate their substrates. 
To attain full catalytic activity, DYRKs 
require phosphorylation at the second 
tyrosine residue of a conserved YxY 
motif in their activation loop. In contrast 
to mitogen-activated protein kinases 
(MAPKs), where activation depends 
on phosphorylation of a TxY motif by 
upstream kinases, DYRKs activate 
themselves during translation by 
intramolecular (cis) autophosphorylation 
(Figure 1A). The mature and active 
kinase then phosphorylates substrates 
on serine and threonine residues in 
a consensus motif that has a proline 
residue carboxy-terminal to the target 
site (RX1-2S/TP). In contrast to former 
assumptions, mammalian DYRK1A (at 
least) retains tyrosine kinase activity 
as a mature protein and is able to 
autophosphorylate tyrosines outside 
the activation loop. 
How were the DYRKs discovered?  
Several DYRK-related kinases were 
identifi ed as developmental regulators 
in genetically tractable organisms. 
The founding member of the DYRK 
family is Yak1, which turned up in a 
screen for negative growth regulators 
in baker’s yeast (Saccharomyces 
cerevisiae). Upregulation of Yak1 
arrests cell proliferation and stimulates 
the cellular stress response to 
promote cell survival. In fi ssion yeast 
(Schizosaccharomyces pombe), a 
gradient of the DYRK homologue 
Quick guideR488 Current Biology 25, R483–R489, Junkinase Pom1 controls cell polarity 
and cytokinesis. Furthermore, 
overexpression of YakA causes cell-
cycle arrest and promotes transition 
from the unicellular to a multicellular 
phase in the social amoeba 
Dictyostelium discoideum. With 
respect to multicellular organisms, a 
screen of Drosophila mutants identifi ed 
a Yak1/DYRK1-related kinase that was 
termed minibrain (mnb): mnb mutant e 15, 2015 ©2015 Elsevier Ltd All rights reservedfl ies have a reduced brain size due to 
abnormal neuroblast proliferation. 
What about mammalian DYRKs? 
The fi ve mammalian DYRK isoforms 
are phylogenetically categorized as 
class I DYRKs (DYRK1A and DYRK1B) 
and class II DYRKs (DYRK2, DYRK3 
and DYRK4). The high degree of 
sequence similarity with DYRKs in 
lower eukaryotes suggests that the 
Current Biology
Magazinefunctional properties of mammalian 
DYRKs are conserved. Indeed, they 
also act as negative regulators of 
the cell cycle. DYRK1A in particular 
regulates the length of G1 phase in 
various cell types and modulates 
the decision between cell-cycle re-
entry and cell-cycle exit (Figure 1B). 
Thus, DYRK1A seems to be a master 
regulator of cell proliferation and 
quiescence or differentiation. DYRK1B 
appears to have similar functions in a 
more limited spectrum of cell types. 
For instance, DYRK1B is upregulated 
when myoblasts differentiate and 
is involved in muscle development. 
Furthermore, overexpression or 
activation of DYRK1B in cancer or 
during the course of a stress response 
can drive cell cycle arrest to allow 
repair and/or cell survival.
Among class II DYRKs, DYRK2 
is also a negative regulator of 
S-phase entry and was found to be 
underexpressed in tumors. DYRK3 
plays a role in erythropoiesis, where it 
reduces cell cycling and expansion of 
early stage erythroblasts. Although the 
function of DYRK4 remains obscure, 
it is obvious that cell-cycle regulation 
is a major function of mammalian 
DYRKs.
Do DYRKs have functions other 
than cell-cycle control? Absolutely! 
As the best characterized member of 
the family, DYRK1A has been virtually 
overloaded with diverse functions in 
chromatin remodeling, transcriptional 
control, alternative mRNA splicing, 
homocysteine metabolism, circadian 
timekeeping, cardiomyocyte 
hypertrophy, electrophysiological 
properties and synaptic function in 
neurons, which is by no means a 
comprehensive list. Transgenic mouse 
strains with an extra copy of the 
DYRK1A gene as well as mice with a 
heterozygous loss-of-function allele 
of DYRK1A have provided insights 
into the roles of DYRK1A in neuronal 
development, synaptic transmission 
and neurodegeneration. Although 
some of the proposed functions 
require further confi rmation, DYRK1A 
is undoubtedly a pleiotropic kinase 
with important roles in many different 
cellular processes. 
How do DYRKs fulfi l these 
functions? DYRKs alter the turnover of target proteins by phosphorylating 
residues that inhibit or activate 
protein degradation. For example, 
DYRK1A and DYRK1B phosphorylate 
the cell-cycle regulators p27Kip1 
and cyclin D1 at sites that affect 
their protein turnover during G1 
phase (Figure 1B). Besides direct 
phosphorylation, DYRKs also operate 
as priming kinases for subsequent 
phosphorylation of targets by 
glycogen synthase kinase 3 (GSK3), as 
exemplifi ed in the case of the c-Myc 
oncoprotein and the microtubule-
associated protein tau. DYRKs, in 
particular DYRK1A, regulate gene 
expression on multiple levels, including 
direct effects on transcription factors, 
effects on histone modifi cation and 
the phosphorylation of the carboxy-
terminal domain of RNA polymerase 
II. The protein kinase activity appears 
to be essential for most functions of 
DYRKs, although the non-catalytic 
domains can act as scaffolds for 
signaling complexes. 
Are DYRKs clinically relevant? 
DYRK1A attracts vast attention 
due to its association with genetic 
diseases. Because of its localization 
on chromosome 21, the DYRK1A 
gene is 1.5-fold overexpressed 
in trisomy 21. Increased activity 
of DYRK1A has been correlated 
with abnormal brain development, 
cognitive disabilities and an early 
onset of Alzheimer’s disease in 
individuals with Down syndrome. 
In particular, overexpression of 
DYRK1A impairs neurodevelopment 
by deregulating cell-cycle progression 
and differentiation of neuronal 
precursors. Hyperphosphorylation 
of tau and other Alzheimer-related 
neuronal target proteins by DYRK1A 
potentially contributes to early 
neurodegeneration in Down syndrome 
as well as to Alzheimer’s disease in 
the normal population (Figure 1C). 
The proposed role in Down 
syndrome implies that DYRK1A is 
a highly dosage-sensitive gene. 
In support of this assumption, 
heterozygous disruption of the 
DYRK1A gene causes a rare syndrome 
called MRD7 (mental retardation, 
autosomal dominant 7, OMIM 
entry #614104). These patients are 
characterized by microcephaly, 
severe mental retardation, autistic Current Biology 25, R483–R489, June 15, 2015 behavior and seizures. Moreover, 
de novo mutations of DYRK1A 
have been identifi ed in families with 
cases of sporadic autism spectrum 
disorder. Taken together, the clinical 
evidence strongly supports the idea 
that DYRK1A has a key role in brain 
development. 
DYRK1B has received attention as 
a potential oncogenic driver, because 
the DYRK1B gene is overexpressed 
in certain cancer types. New interest 
was recently sparked by the discovery 
that a gain-of-function mutation 
of the DYRK1B gene is causative 
for a familial form of the metabolic 
syndrome. 
Might some DYRKs serve as drug 
targets? The increased activity 
of DYRK1A in Down syndrome 
is in principle accessible to 
pharmacological intervention with 
kinase inhibitors. However, the 
delicate dose-dependency observed 
for the phenotypic effects of the 
DYRK1A gene counsels caution, at 
least regarding prenatal therapy. The 
accumulating evidence for a role of 
DYRK1A in Alzheimer’s disease has 
further boosted the search for potent 
and specifi c inhibitors of DYRK1A. 
Beyond that, DYRK1A and DYRK1B 
are considered as therapeutic targets 
in cancer therapy, because they can 
drive cell-cycle exit and quiescence 
of tumour cells. Hence, DYRK1 
inhibitors might promote cell-cycle 
re-entry of quiescent tumour cells and 
thereby increase their susceptibility to 
chemotherapy or radiotherapy.
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